Aeglea BioTherapeutics Inc.

0.3300+0.0045+1.38%Vol 57.77K1Y Perf -87.72%
Mar 22nd, 2023 14:19 DELAYED
BID0.3301 ASK0.3380
Open0.3270 Previous Close0.3255
Pre-Market0.30 After-Market-
 -0.03 -7.74%  - -
Target Price
1.88 
Analyst Rating
Moderate Buy 1.80
Potential %
469.70 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/100/100 
Value Ranking
★★★     51.74
Insiders Value % 3/6/12 mo.
-/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
1.05 
Earnings Rating
Strong Buy
Market Cap21.58M 
Earnings Date
4th May 2023
Alpha-0.03 Standard Deviation0.21
Beta1.94 

Today's Price Range

0.32600.3473

52W Range

0.30003.17

5 Year PE Ratio Range

-2.80-4.40

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
5.14%
1 Month
-29.16%
3 Months
-8.34%
6 Months
-29.55%
1 Year
-87.72%
3 Years
-91.84%
5 Years
-96.90%
10 Years
-

TickerPriceChg.Chg.%
AGLE0.33000.00451.38
AAPL161.582.29991.44
GOOG107.101.26001.19
MSFT280.076.29002.30
XOM106.87-0.1700-0.16
WFC38.41-0.0700-0.18
JNJ152.96-0.9301-0.60
FB196.640.99000.51
GE92.230.05000.05
JPM129.90-0.6501-0.50
 
ProfitabilityValueIndustryS&P 500US Markets
-
-1 482.50
-1 455.10
-691.80
-
RevenueValueIndustryS&P 500US Markets
2.16M
0.04
-
-
Earnings HistoryEstimateReportedSurprise %
Q04 2022-0.20-0.1810.00
Q03 2022-0.24-0.1920.83
Q02 2022-0.26-0.27-3.85
Q01 2022-0.35-0.37-5.71
Q04 2021-0.32-0.313.12
Q03 2021-0.29-0.31-6.90
Q02 2021-0.19-0.1047.37
Q01 2021-0.13-0.28-115.38
Earnings Per EndEstimateRevision %Trend
12/2022 QR-0.2013.04Positive
12/2022 FY-1.017.34Positive
3/2023 QR-0.2016.67Positive
12/2023 FY-0.811.22Positive
Next Report Date4th May 2023
Estimated EPS Next Report-0.20
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume57.77K
Shares Outstanding65.40K
Shares Float56.61M
Trades Count177
Dollar Volume19.18K
Avg. Volume273.14K
Avg. Weekly Volume257.89K
Avg. Monthly Volume231.71K
Avg. Quarterly Volume329.81K

Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) stock closed at 0.3255 per share at the end of the most recent trading day (a 8.5% change compared to the prior day closing price) with a volume of 197.61K shares and market capitalization of 21.58M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 87 people. Aeglea BioTherapeutics Inc. CEO is Anthony G. Quinn.

The one-year performance of Aeglea BioTherapeutics Inc. stock is -87.72%, while year-to-date (YTD) performance is -27.65%. AGLE stock has a five-year performance of -96.9%. Its 52-week range is between 0.3 and 3.17, which gives AGLE stock a 52-week price range ratio of 1.05%

Aeglea BioTherapeutics Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.46, a price-to-sale (PS) ratio of 14.37, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -77.45%, a ROC of -95.69% and a ROE of -100.73%. The company’s profit margin is -%, its EBITDA margin is -1 455.10%, and its revenue ttm is $2.16 Million , which makes it $0.04 revenue per share.

Of the last four earnings reports from Aeglea BioTherapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.20 for the next earnings report. Aeglea BioTherapeutics Inc.’s next earnings report date is 04th May 2023.

The consensus rating of Wall Street analysts for Aeglea BioTherapeutics Inc. is Moderate Buy (1.8), with a target price of $1.88, which is +469.70% compared to the current price. The earnings rating for Aeglea BioTherapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aeglea BioTherapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aeglea BioTherapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 7.81, ATR14 : 0.05, CCI20 : -127.71, Chaikin Money Flow : -0.36, MACD : -0.04, Money Flow Index : 36.12, ROC : -17.39, RSI : 36.56, STOCH (14,3) : 15.94, STOCH RSI : 1.00, UO : 30.77, Williams %R : -84.06), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aeglea BioTherapeutics Inc. in the last 12-months were: Marcio Souza (Buy at a value of $50 472), Michael Conick Hanley (Buy at a value of $20 022)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (60.00 %)
3 (60.00 %)
3 (60.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (40.00 %)
2 (40.00 %)
2 (40.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.80
Moderate Buy
1.80
Moderate Buy
1.80

Aeglea BioTherapeutics Inc.

Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage.

CEO: Anthony G. Quinn

Telephone: +1 512 942-2935

Address: 805 Las Cimas Parkway, Austin 78746, TX, US

Number of employees: 87

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

61%39%

Bearish Bullish

62%38%

Bearish Bullish

61%39%


News

Stocktwits